• All
  • Financials
  • Insiders
Webull provides the latest VAXART (VXRT) stock and general news. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc. is a clinical-stage biotechnology company. The Company is focused on developing oral recombinant vaccines based on its vector-adjuvant-antigen standardized technology (VAAST) proprietary oral vaccine platform. Its oral vaccines are designed to generate immune responses that protect against a range of infectious diseases and will be useful for the treatment of chronic viral infections and cancer. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), norovirus, seasonal influenza and respiratory syncytial virus (RSV). The Company is also developing therapeutic vaccine targeting cervical cancer and dysplasia caused by human papillomavirus (HPV).